

Australian and New Zealand Clinical Trials Registry Advisory Board

Role/Objective

The role of the Australian and New Zealand Clinical Trials Registry (ANZCTR) Advisory Board is to provide the National Health and Medical Research Council (NHMRC) and the Therapeutic Goods Administration (TGA) with advice in relation to the implementation, operation and development of the ANZCTR.

Specifically, the ANZCTR Advisory Board will provide advice on the following matters:

- the operation of the ANZCTR, having regard to consumer, industry and government perspectives;
- accessibility of information contained in the ANZCTR;
- the scope of clinical interventions to be included in the ANZCTR;
- process(es) for the mandatory registration of clinical trials;
- treatment of commercially sensitive information;
- the minimum data set for the registry;
- review of the ANZCTR;
- issues affecting the long-term sustainability of the ANZCTR;
- international obligations/links; and
- other matters relevant to the implementation, operation and development of the ANZCTR or the Advisory Board, as may be requested by the NHMRC (through its appropriate committees) or the TGA.

Standing

The ANZCTR Advisory Board is being established as a working committee of the NHMRC. Members are covered for legal liability and costs in a manner consistent with other NHMRC committees. The Consumer Representative will be entitled to a sitting fee and coverage of travel costs. All positions are on a part-time basis.

Membership

The Advisory Board will consist of up to 13 members filling the positions listed below:

1. Chief Medical Officer (or nominee);
2. National Manager of the TGA (or nominee);
3. Nominee of the TGA;
4. Chief Executive Officer of the NHMRC (or nominee);
5. Nominee of the University of Sydney;
6. Chief Investigator A of the ANZCTR Project (ex officio member);
7. Member or nominee of the NHMRC Research Committee;
8. Member or nominee of the Australian Health Ethics Committee (AHEC) with knowledge of human research ethics at the institution level;
9. Industry representative;
10. Representative of the Clinical Research Community;
11. Editor of an ICMJE affiliated Medical Journal, preferably Australian based;

12. Health consumer advocate; and
13. Chief Executive of the Health Research Council of New Zealand (or nominee).

All appointed members of the Advisory Board may use an alternate if unable to attend a meeting.

Timeframe

Appointment shall be for a term not exceeding three years. Further appointments may be offered. It is anticipated that initial appointments will commence from January 2006.

Appointment of a Consumer Representative

The NHMRC has strongly recommended that the consumer representative has relevant experience in the conduct of clinical trials. The consumer representative will be appointed on the basis of his/her expertise and not as a representative of his/her employer or advocacy group.

Selection Criteria

The person we are seeking understands the consumer issues that arise in medical research and, in particular, clinical trials. The person has represented health consumers, and may have written submissions to government, or spoken at conferences.

The person has consulted with non-government organisations, patient support or consumer groups. The person is able to build collaborative relationships with government, industry, patients and medical researchers.

This role involves attendance at meetings, which will be held in Sydney, Melbourne or Canberra. Applicants with an interest in the position are invited to supply a short (one-page) expression of interest, resume and the contact details for two referees.

Applications addressing the selection criteria should be forwarded to the following address:

National Health and Medical Research Council
Collaborations and Researcher Support Section
Attn: Mr Michael Nutt
GPO Box 9898
Canberra ACT 2601

or submitted via email to enabling@nhmrc.gov.au.

The closing date for applications is 19 December 2005.